BR112017011490A2 - método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente - Google Patents

método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente

Info

Publication number
BR112017011490A2
BR112017011490A2 BR112017011490A BR112017011490A BR112017011490A2 BR 112017011490 A2 BR112017011490 A2 BR 112017011490A2 BR 112017011490 A BR112017011490 A BR 112017011490A BR 112017011490 A BR112017011490 A BR 112017011490A BR 112017011490 A2 BR112017011490 A2 BR 112017011490A2
Authority
BR
Brazil
Prior art keywords
organ
tissue
patient
inflammatory condition
treating ischemic
Prior art date
Application number
BR112017011490A
Other languages
English (en)
Inventor
S Penn Marc
Mayorga Maritza
Kiedrowski Matthew
Original Assignee
Northeast Ohio Medical Univ
Summa Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northeast Ohio Medical Univ, Summa Health filed Critical Northeast Ohio Medical Univ
Publication of BR112017011490A2 publication Critical patent/BR112017011490A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11017—Ca2+/Calmodulin-dependent protein kinase (2.7.11.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hematology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)

Abstract

métodos para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente são aqui divulgados, caracterizados por que compreendem induzir um aumento do nível de camkk1 no referido órgão ou tecido.
BR112017011490A 2014-12-01 2015-12-01 método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente BR112017011490A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Publications (1)

Publication Number Publication Date
BR112017011490A2 true BR112017011490A2 (pt) 2018-02-27

Family

ID=56092307

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011490A BR112017011490A2 (pt) 2014-12-01 2015-12-01 método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente

Country Status (13)

Country Link
US (2) US11273208B2 (pt)
EP (2) EP3940068A1 (pt)
JP (2) JP6893873B2 (pt)
KR (3) KR102236843B1 (pt)
AU (1) AU2015355188B2 (pt)
BR (1) BR112017011490A2 (pt)
CA (1) CA3007055C (pt)
CL (1) CL2017001390A1 (pt)
CR (1) CR20170301A (pt)
IL (2) IL252612B (pt)
RU (1) RU2017122817A (pt)
UA (1) UA124450C2 (pt)
WO (1) WO2016089826A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA124450C2 (uk) 2014-12-01 2021-09-22 Самма Хелт Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта
US20210113662A1 (en) * 2018-04-18 2021-04-22 Summa Health Compositions and methods for the treatment of ischemia and cardiomyopathy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002072115A2 (en) 2001-03-09 2002-09-19 Board Of Regents, The University Of Texas System Vectors, compositions and methods for treating a vascular disorder
WO2006124013A2 (en) 2004-04-30 2006-11-23 Five Prime Therapeutics, Inc. Novel stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof, and method of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
WO2006015127A2 (en) * 2004-07-30 2006-02-09 Mayo Foundation For Medical Education And Research Treating cardiovascular tissue
AU2005287855B2 (en) 2004-09-24 2011-06-16 Mesoblast, Inc. Method of enhancing proliferation and/or survival of mesenchymal precursor cells (MPC)
US20090246179A1 (en) 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2687219A1 (en) 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
US20160206550A1 (en) * 2013-08-29 2016-07-21 Stempeutics Research Pvt. Ltd. Stromal dells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
UA124450C2 (uk) 2014-12-01 2021-09-22 Самма Хелт Спосіб індукції відновлення серця або міокарда або поліпшення функції вказаного серця або міокарда пацієнта
JP6797803B2 (ja) 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法

Also Published As

Publication number Publication date
IL252612B (en) 2021-07-29
KR20170088988A (ko) 2017-08-02
EP3227441A4 (en) 2018-08-15
WO2016089826A1 (en) 2016-06-09
RU2017122817A3 (pt) 2019-06-11
KR102460983B1 (ko) 2022-10-31
CA3007055C (en) 2023-08-01
EP3227441B1 (en) 2021-06-30
JP2018502838A (ja) 2018-02-01
IL284408B (en) 2022-06-01
US20170340712A1 (en) 2017-11-30
RU2017122817A (ru) 2019-01-10
KR20220151004A (ko) 2022-11-11
EP3940068A1 (en) 2022-01-19
AU2015355188A1 (en) 2017-07-20
US20220233653A1 (en) 2022-07-28
KR20210010662A (ko) 2021-01-27
UA124450C2 (uk) 2021-09-22
CL2017001390A1 (es) 2018-05-11
JP6893873B2 (ja) 2021-06-23
CA3007055A1 (en) 2016-06-09
JP2021098717A (ja) 2021-07-01
KR102236843B1 (ko) 2021-04-07
EP3227441A1 (en) 2017-10-11
US11273208B2 (en) 2022-03-15
IL252612A0 (en) 2017-07-31
AU2015355188B2 (en) 2021-08-26
IL284408A (en) 2021-07-29
CR20170301A (es) 2018-02-01
KR102610068B1 (ko) 2023-12-06

Similar Documents

Publication Publication Date Title
HK1245010A1 (zh) 用於治療疾病的遺傳修飾的細胞、組織和器官
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
GB2541571A (en) Pharmaceutical compositions
BR112016029864A2 (pt) métodos e dispositivos para tratamento de desordens oculares posteriores.
BR112014021104A2 (pt) métodos e composições para o tratamento da doença de huntington
BR112016018477A2 (pt) aparelho; e método para realização de um procedimento em um lúmen de corpo e/ou cavidade de corpo.
EA201790802A1 (ru) Соединения против tnf
EA201891340A1 (ru) Лечение рака с использованием 2-дезокси-2-фтор-l-фукозы в комбинации с ингибитором контрольных точек
BR112017005598A2 (pt) macrociclos peptidomiméticos e usos dos mesmos
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
CY1122615T1 (el) Θεραπεια με βλαστοκυτταρα σε παθολογιες τουενδομητριου
BR112018069303A2 (pt) método para tratamento de uma infecção
EA201790019A1 (ru) Способ выбора персонализированной трехкомпонентной терапии для лечения рака
BR112018070497A2 (pt) métodos e formulações farmacêuticas para tratamento de condições oculares
GB2561300B (en) Method and system for diagnosing disease and generating treatment recommendations
EA201991360A1 (ru) Модифицированные олигонуклеотиды для лечения поликистозной болезни почек
PH12017500602A1 (en) Methods for treating ocular conditions
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
EA201691493A1 (ru) Замещенные n-арилпиридиноны
BR112016024047A2 (pt) sistemas e métodos para melhorar função de órgão ou tecido e longevidade de transplante de órgão ou tecido.
BR112017011490A2 (pt) método para tratar condição inflamatória ou isquêmica em um órgão ou tecido de um paciente
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
BR112018068798A2 (pt) composições e métodos para tratamento de doenças parasíticas
BR112016029238A2 (pt) método e aparelhos para fornecer uma solução para o tratamento de sangue.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C12N 15/54

Ipc: A61K 38/45 (2006.01), A61K 48/00 (2006.01), C12N 9

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]